{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:19:25Z","timestamp":1791580765091,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"HuVet Bio Inc","award":["non-applicable"],"award-info":[{"award-number":["non-applicable"]}]},{"name":"MSI","award":["IITP-2025-2020-0-01789"],"award-info":[{"award-number":["IITP-2025-2020-0-01789"]}]},{"name":"IIT","award":["IITP-2025-RS-2023-00254592"],"award-info":[{"award-number":["IITP-2025-RS-2023-00254592"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies and most often diagnosed at an advanced stage. Identification of markers for the early diagnosis of PDAC is crucial. In this study, we aimed to identify novel mRNA biomarkers for diagnosing PDAC, focusing on early-stage tumorigenesis and associated immunological changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Blood samples and clinical information from 1,963 individuals were obtained from a single tertiary hospital between 2015 and 2021. Candidate mRNA biomarkers were identified through literature review, and their expression levels in buffy coat samples were measured using reverse-transcription quantitative polymerase chain reaction. Machine learning-based feature selection confirmed the final biomarker panel, which was tested using an independent dataset for diagnostic performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 1,504 individuals (417 patients with PDAC and 1,087 non-disease controls) were eligible for the study. Among the 55 candidate biomarkers identified, 15 mRNAs (\n                      <jats:italic>CCL5<\/jats:italic>\n                      ,\n                      <jats:italic>CCR5<\/jats:italic>\n                      ,\n                      <jats:italic>CLEC7A<\/jats:italic>\n                      ,\n                      <jats:italic>CXCL8<\/jats:italic>\n                      ,\n                      <jats:italic>CXCR2<\/jats:italic>\n                      ,\n                      <jats:italic>CXCR4<\/jats:italic>\n                      ,\n                      <jats:italic>FOXP3<\/jats:italic>\n                      ,\n                      <jats:italic>IFNA1<\/jats:italic>\n                      ,\n                      <jats:italic>IFNL1<\/jats:italic>\n                      ,\n                      <jats:italic>PTGES<\/jats:italic>\n                      ,\n                      <jats:italic>PTGES2<\/jats:italic>\n                      ,\n                      <jats:italic>PTGS2<\/jats:italic>\n                      ,\n                      <jats:italic>SLC27A2<\/jats:italic>\n                      ,\n                      <jats:italic>TNF<\/jats:italic>\n                      , and\n                      <jats:italic>VEGFA)<\/jats:italic>\n                      were selected based on their diagnostic performance in distinguishing PDAC from control groups. The final model, HELP-15 (Human Early Liquid biopsy for PDAC), identified all PDAC stages (area under the curve [AUC]\u2009=\u20090.956) in the test set. For resectable pancreatic cancer (RPC), the AUC was 0.968, compared to 0.910 for carbohydrate antigen 19\u2009\u2212\u20099 (CA19-9). The combined model of the panel and CA19-9 achieved an AUC of 0.985 in patients with RPC. For all PDAC stages in patients with normal CA19-9 levels, the AUC of the panel was 0.967, whereas CA19-9 alone or in combination with the panel had AUCs of 0.658 and 0.885, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared to CA19-9, the mRNA biomarker panel, HELP-15, improved diagnostic performance in patients with RPC, particularly in those with normal CA19-9 levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-14124-w","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T05:17:54Z","timestamp":1745385474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel mRNA biomarker-based liquid biopsy for the detection of resectable pancreatic cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Jong-chan","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Won","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jin","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sik","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-mo","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mun-sub","family":"Byoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serin","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangrok","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaihwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung Hwa","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihie","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hyeok","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"14124_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"key":"14124_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1208\/s12248-010-9181-5","volume":"12","author":"J Li","year":"2010","unstructured":"Li J, Wientjes MG, Au JL-S. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J. 2010;12:223\u201332. https:\/\/doi.org\/10.1208\/s12248-010-9181-5.","journal-title":"AAPS J"},{"key":"14124_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3978\/j.issn.1000-9604.2015.07.03","volume":"27","author":"VM Kim","year":"2015","unstructured":"Kim VM, Ahuja N. Early detection of pancreatic cancer. Chin J Cancer Res. 2015;27:321\u201331. https:\/\/doi.org\/10.3978\/j.issn.1000-9604.2015.07.03.","journal-title":"Chin J Cancer Res"},{"key":"14124_CR4","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","volume":"154","author":"RP Jones","year":"2019","unstructured":"Jones RP, Psarelli E-E, Jackson R, Ghaneh P, Halloran CM, Palmer DH, et al. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: A secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg. 2019;154:1038\u201348. https:\/\/doi.org\/10.1001\/jamasurg.2019.3337.","journal-title":"JAMA Surg"},{"key":"14124_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3322\/caac.21626","volume":"70","author":"AJ Grossberg","year":"2020","unstructured":"Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70:375\u2013403. https:\/\/doi.org\/10.3322\/caac.21626.","journal-title":"CA Cancer J Clin"},{"key":"14124_CR6","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846\u201361. https:\/\/doi.org\/10.3748\/wjg.v24.i43.4846.","journal-title":"World J Gastroenterol"},{"key":"14124_CR7","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1056\/NEJMra1404198","volume":"371","author":"DP Ryan","year":"2014","unstructured":"Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039\u201349. https:\/\/doi.org\/10.1056\/NEJMra1404198.","journal-title":"N Engl J Med"},{"key":"14124_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ijc.26422","volume":"131","author":"J Liu","year":"2012","unstructured":"Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, et al. Combination of plasma MicroRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer. 2012;131:683\u201391. https:\/\/doi.org\/10.1002\/ijc.26422. Epub November 19, 2011.","journal-title":"Int J Cancer"},{"key":"14124_CR9","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/2211-5463.12278","volume":"7","author":"M Guo","year":"2017","unstructured":"Guo M, Luo G, Lu R, Shi W, Cheng H, Lu Y, et al. Distribution of Lewis and secretor polymorphisms and corresponding CA19-9 antigen expression in a Chinese population. FEBS Open Bio. 2017;7:1660\u201371. https:\/\/doi.org\/10.1002\/2211-5463.12278. eCollection.","journal-title":"FEBS Open Bio"},{"key":"14124_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S2468-1253(16)30113-3","volume":"1","author":"S Macdonald","year":"2016","unstructured":"Macdonald S, Mair F. Tackling cancers of unmet need: the pancreatic cancer pathway. Lancet Gastroenterol Hepatol. 2016;1:266\u20137. https:\/\/doi.org\/10.1016\/S2468-1253(16)30113-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"14124_CR11","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926\u201330. https:\/\/doi.org\/10.1126\/science.aar3247.","journal-title":"Science"},{"key":"14124_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745\u201359. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.011.","journal-title":"Ann Oncol"},{"key":"14124_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrclinonc.2018.21","volume":"15","author":"D Killock","year":"2018","unstructured":"Killock D, Diagnosis. CancerSEEK and destroy \u2013 A blood test for early cancer detection. Nat Rev Clin Oncol. 2018;15:133. https:\/\/doi.org\/10.1038\/nrclinonc.2018.21.","journal-title":"Nat Rev Clin Oncol"},{"key":"14124_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2016.193","volume":"16","author":"Y Shi","year":"2017","unstructured":"Shi Y, Du L, Lin L, Wang Y. Tumour-associated mesenchymal stem\/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov. 2017;16:35\u201352. https:\/\/doi.org\/10.1038\/nrd.2016.193.","journal-title":"Nat Rev Drug Discov"},{"key":"14124_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41419-019-2149-1","volume":"10","author":"B Sai","year":"2019","unstructured":"Sai B, Dai Y, Fan S, Wang F, Wang L, Li Z, et al. Cancer-educated mesenchymal stem cells promote the survival of cancer cells at primary and distant metastatic sites via the expansion of bone marrow-derived-PMN-MDSCs. Cell Death Dis. 2019;10:941. https:\/\/doi.org\/10.1038\/s41419-019-2149-1.","journal-title":"Cell Death Dis"},{"key":"14124_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neo.2016.01.005","volume":"18","author":"E Mathew","year":"2016","unstructured":"Mathew E, Brannon AL, Del Vecchio AC, Garcia PE, Penny MK, Kane KT, et al. Mesenchymal stem cells promote pancreatic tumor growth by inducing alternative polarization of macrophages. Neoplasia. 2016;18:142\u201351. https:\/\/doi.org\/10.1016\/j.neo.2016.01.005.","journal-title":"Neoplasia"},{"key":"14124_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/2159-8290.CD-15-0947","volume":"6","author":"M Waghray","year":"2016","unstructured":"Waghray M, Yalamanchili M, Dziubinski M, Zeinali M, Erkkinen M, Yang H, et al. GM-CSF mediates mesenchymal-epithelial cross-talk in pancreatic cancer. Cancer Discov. 2016;6:886\u201399. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0947.","journal-title":"Cancer Discov"},{"key":"14124_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","volume":"569","author":"F Veglia","year":"2019","unstructured":"Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkov AV, Donthireddy L, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 2019;569:73\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1118-2.","journal-title":"Nature"},{"key":"14124_CR19","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines [Internet]. Available from: https:\/\/www.nccn.org\/guidelines\/category_1"},{"key":"14124_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"14124_CR21","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.7150\/jca.38048","volume":"11","author":"J Wei","year":"2020","unstructured":"Wei J, Yang L, Wu Y-N, Xu J. Serum miR-1290 and miR-1246 as potential diagnostic biomarkers of human pancreatic cancer. J Cancer. 2020;11:1325\u201333. https:\/\/doi.org\/10.7150\/jca.38048.","journal-title":"J Cancer"},{"key":"14124_CR22","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1038\/s41467-020-18965-w","volume":"11","author":"GD Guler","year":"2020","unstructured":"Guler GD, Ning Y, Ku C-J, Phillips T, McCarthy E, Ellison CK, et al. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in Circulating cell free DNA. Nat Commun. 2020;11:5270. https:\/\/doi.org\/10.1038\/s41467-020-18965-w.","journal-title":"Nat Commun"},{"key":"14124_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrc.2016.153","volume":"17","author":"CAK Borrebaeck","year":"2017","unstructured":"Borrebaeck CAK. Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nat Rev Cancer. 2017;17:199\u2013204. https:\/\/doi.org\/10.1038\/nrc.2016.153.","journal-title":"Nat Rev Cancer"},{"key":"14124_CR24","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","volume":"32","author":"EA Klein","year":"2021","unstructured":"Klein EA, Richards D, Cohn A, Tummala M, Tummala M, Lapham R, Cosgrove D, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32:1167\u201377. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.806.","journal-title":"Ann Oncol"},{"key":"14124_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/jhbp.986","volume":"30","author":"D-H Lee","year":"2023","unstructured":"Lee D-H, Yoon W, Lee A, Han Y, Byun Y, Kang JS, et al. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Sci. 2023;30:122\u201332. https:\/\/doi.org\/10.1002\/jhbp.986.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"14124_CR26","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1053\/j.gastro.2022.06.090","volume":"163","author":"K Nakamura","year":"2022","unstructured":"Nakamura K, Zhu Z, Roy S, Jun E, Han H, Munoz RM, et al. An exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: A multicenter cohort study. Gastroenterology. 2022;163:1252\u201366..e2.","journal-title":"Gastroenterology"},{"key":"14124_CR27","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00345-018-2380-x","volume":"36","author":"F Soria","year":"2018","unstructured":"Soria F, Droller MJ, Lotan Y, Gontero P, D\u2019Andrea D, Gust KM, et al. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World J Urol. 2018;36:1981\u201395. https:\/\/doi.org\/10.1007\/s00345-018-2380-x.","journal-title":"World J Urol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14124-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14124-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14124-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T05:17:58Z","timestamp":1745385478000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14124-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14124"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14124-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5119465\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We obtained ethics approvals from the Human Bioresource Center of the Seoul National University Bundang Hospital (Affiliated College of Medicine, Seoul National University). The study was reviewed and approved by the Institutional Review Board (IRB approval number: X-2011-651-903) and was conducted in accordance with the Declaration of Helsinki. Private patient information was anonymized and de-identified prior to analysis. (Official full name of the ethics committee that approved this study is Seoul National University Bundang Hospital Institutional Review, and the name of institute is Seoul National University Bundang Hospital.)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jin-Hyeok Hwang and Jihie Kim declare conflict of interest including advisory committee of HuVet bio Inc. Hyoung-Hwa Jeong is a CEO of HuVet bio Inc. Other authors have no COI to declare. All participants provided informed consent under the condition of guaranteed anonymity when donating their samples to the Human Resources Center at Seoul National University Bundang Hospital. The consent included the following components: (1) donation of blood or tissue samples, (2) provision of basic clinical information, and (3) exemption from the requirement of obtaining additional consent for future related research. The institutional Review Board of Seoul National University Bundang Hospital granted comprehensive ethical approval for the use of these samples in subsequent secondary and tertiary studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"762"}}